As of June 2024 BioCryst Pharmaceuticals has a market cap of $1.30 Billion. This makes BioCryst Pharmaceuticals the world's 4787th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Year | Market cap | Change |
---|---|---|
2024 | $1.30 B | 6.15% |
2023 | $1.22 B | -42.68% |
2022 | $2.14 B | -14.12% |
2021 | $2.49 B | 89.45% |
2020 | $1.31 B | 147.45% |
2019 | $0.53 B | -40.15% |
2018 | $0.88 B | 83.83% |
2017 | $0.48 B | 3.49% |
2016 | $0.46 B | -38.33% |
2015 | $0.75 B | -13.48% |
2014 | $0.87 B | 94.83% |
2013 | $0.44 B | 521.44% |
2012 | $72.26 M | -35.29% |
2011 | $0.11 B | -51.95% |
2010 | $0.23 B | -18.05% |
2009 | $0.28 B | 441.16% |
2008 | $52.41 M | -77.66% |
2007 | $0.23 B | -30.6% |
2006 | $0.33 B | -29.94% |
2005 | $0.48 B | 283.76% |
2004 | $0.12 B | 2.73% |
2003 | $0.12 B | 622.2% |
2002 | $16.95 M | -75.69% |
2001 | $69.72 M |
On Jun 9th, 2024 the market cap of BioCryst Pharmaceuticals was reported to be:
Name | Market cap | Market cap differencediff. | Country |
---|---|---|---|
Gilead Sciences GILD | $80.60 B | 6,089.84% | ๐บ๐ธ USA |
GlaxoSmithKline GSK | $85.55 B | 6,469.70% | ๐ฌ๐ง UK |
Sarepta Therapeutics
SRPT | $11.65 B | 795.13% | ๐บ๐ธ USA |
Repligen
RGEN | $8.14 B | 525.51% | ๐บ๐ธ USA |
Novavax NVAX | $2.67 B | 105.52% | ๐บ๐ธ USA |
Celldex Therapeutics CLDX | $2.32 B | 78.56% | ๐บ๐ธ USA |
NanoViricides NNVC | $31.54 M | -97.58% | ๐บ๐ธ USA |
Cel-Sci
CVM | $70.4 M | -94.59% | ๐บ๐ธ USA |
Emergent BioSolutions
EBS | $0.32 B | -75.09% | ๐บ๐ธ USA |